01/24/16 - 02:00 PM EST
Biotech stocks are buried in a deep hole. To climb out, companies will have to generate some positive news.
01/24/16 - 11:00 AM EST
TheStreet's Adam Feuerstein responds to reader questions about Sarepta and its Duchenne muscular dystrophy drug eteplirsen.
01/21/16 - 08:27 AM EST
Alkermes said Thursday the experimental drug ALKS 5461 failed to improve depressive symptoms in patients with hard-to-treat depression, based on negative results from two late-stage clinical trials.
01/19/16 - 07:19 AM EST
Acorda's all-cash tender offer values Biotie at $363 million, or $25.60 per ADS, representing a 96% premium over the stock's closing price on Friday.
01/15/16 - 12:25 PM EST
The FDA's review team appears to cast significant doubt on eteplirsen's approval chances.
01/13/16 - 12:29 PM EST
Nothing at the J.P. Morgan Healthcare Conference is convincing health care investors to step up and buy biotech stocks.
01/11/16 - 04:25 PM EST
Biotech stocks large and small were plummeting as 2016's painful start began to turn torturous.
01/11/16 - 06:51 AM EST
A much-hyped press conference reveals nothing new about Brainstorm's stem-cell therapy for ALS.
01/10/16 - 04:58 PM EST
Vertex presents to investors on Monday at the J.P. Morgan Healthcare Conference.
01/09/16 - 03:00 PM EST
I'm only making one big prediction this year: The five-year party which saw biotech stocks outperform the broader markets comes to an end in 2016.